Efficacy and Safety of Bimekizumab in Patients With Moderate to Severe Plaque Psoriasis: Results from BE READY, a 56-Week Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study With Randomized Withdrawal. J of Skin 2020, 4 (6), s83. https://doi.org/10.25251/skin.4.supp.83.